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Interactions are occurring in the course of liberation, absorption, distribution, metabolism,
and excretion of active ingredients, or at the target receptors. They are causing therapy
failures and undesirable events. Forty-seven of fifty-seven human hepatic isoenzymes are
specific and relevant in hormone and vitamin metabolism and biosynthesis. Aromatase
(syn. CYP19A1) is one of the specific CYP450 isoenzymes so far not elucidated in detail.
As aromatase-inhibiting phytochemicals are currently recommended for breast cancer
prevention and as add-on accompanying aromatase-inhibitor pharmacotherapy, it was
the aim of this literature review to assess whether a common interpretation on genetic
and -omics basis could be found. Articles retrieved showed that traditional antioxidation
diet is one of the most approved explanations of inhibition of aromatase by phytonutrients
of flavonoid derivatives. Flavonoids compete for the oxygen provided by the hememoiety
of aromatase in the course of aromatase-catalyzed conversion of steroid precursors to
estrogens. Flavonoids are therefore promoted for breast cancer prevention. A further
explanation of flavonoids’ mechanism of action proposed was related to enzymatic
histone deacetylation. By keeping DNA-structure wide through a high acetylation degree,
acetylated histones favor transcription and replication. This mechanism corresponds
to a procedure of switching genes on. Inhibiting acetylation and therefore switching
genes off might be an important regulation of repressing cancer genes. Aromatase
expression depends on the genotype and phenotype of a person. Aromatase itself
depends on the expression of the heme moiety encoded in the genotype. Biosynthesis
of porphyrins in turn depends on the substrates succinate and glycine, as well as
on a series of further enzymes, with ALA synthetase as the rate-limiting step. The
effect of the heme moiety as prosthetic group of aromatase further depends on the
absorption of iron as a function of pH and redox state. To assess the function of
aromatase precisely, multiple underlying biochemical pathways need to be evaluated.
As a conclusion, the genetic regulation of metabolism is a complex procedure affecting
multiple pathways. To understand a metabolic step, multiple underlying individually
performing reactions need to be considered if personalized (nutritional) medicine should
bring an advantage for a patient. Nutrition sciences need to consider the genome
of an individual to truly find answers to nutrition-derived non-communicable diseases.
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With current GWAS (genome-wide association study) approaches, inherited errors of
metabolism are identified and ideally treated effectively. It is much more difficult to get
a precise genetic profile for non-communicable diseases stemming from multifactorial
causes. Polygenic risks evaluation is feasible but diagnostic tools are not yet available in
a desired extent. Neither flavonoid researchers nor providers of genetic testing kits are
going into the details needed for a truly personalized nutritional medicine. The next step
with profiling the exome and then the whole genome is on the threshold of becoming
routine diagnosis and of bringing the desired details.
Keywords: nutrients, nutrigenomics, aromatase, CYP19A1 isoenzyme, food-drug interactions, healthy aging,
personalized nutritional medicine, flavonoids
INTRODUCTION
Healthy aging, individual lifestyle, and personalized medicine are
an attempt to square the circle. Instead of a progredient decline
of an aging person’s health, disability-free survival is expected to
persist until the person’s sudden death. It is not well-understood
how disability-free survival can be achieved, whether to just live
and accept one’s fate or to order a genetic testing and apply
suitable preventative measures.
There are many examples of senior athletes still able to
perform at highest levels, sometimes to break rules such as “they
will never come back.” Playing tennis in the top 10 even at an age
of almost 40 years, playing in ice-hockey top leagues until aged
more than 40 years, have been proven to be feasible. Obviously,
adaption is one of the keys to remain competitive (1). It is
however more difficult for ordinary people to maintain health
and performance at later phases of life.
To prevent a progredient decrease in the quality of life,
various recommendations are brought to the market often for
commercial purposes and seldom for truly providing more
quality of life nor evident added value (2, 3). Nutritional behavior
might contribute to deteriorate chronic non-communicable
diseases. Yet, simple associations with disease incidences
are hardly ever convincingly evident. Overrepresented old
publications are often taken as standard although biases and
confounding factors (4).
Healthy aging might depend on a well-tuned adaption of an
eating behavior to an individual’s metabolism. Apart from diet,
physical activity is promoted to maintain a person’s and the
population’s health. However, one-fits-all strategies such as the
“eat the rainbow” mantra or the Swiss Food Pyramid do not
consider personalized nutritional medicine (5). Recommended
daily allowances, e.g., DACH recommendations (6), are based
on epidemiological data arising from the need of defined small
healthy population groups. These general needs are corrected by
two standard deviations and additional amounts to compensate
losses from bad accessibility to nutrients from foodstuff or from
processing. In addition, special physiological conditions such
as pregnancy justify an extra supplement. Recommended daily
allowances are therefore unprecise from a nutritional medicine
point of view as they do not consider adequately individual needs.
Nutrition research is under pressure due to poor
methodologies. Solutions will not come from more and more
papers based on qualitative research or from small randomized
trials (7). Even the Predimed study which has shown a risk
reduction by intake of olive oil and nuts cannot be transferred
simply from the Spanish study population to other ethnicities
with different nutritional behaviors (8). Therefore, methods
have to be expanded or changed. Suitable approaches such
as the use of OMICS technologies show promising results in
finding reasons why individuals response differently to the same
foodstuff or consumption of plant food1.
Consuming a number of diets without reflection is not a
suitable strategy for healthy aging. Once food and medicines
are consumed, interactions are occurring in the course of
liberation, absorption, distribution, metabolism, and excretion
of active ingredients, or at the target receptors. They are
causing therapy failures and undesirable events. As only some
10 of 57 human hepatic non-specific CYP450 isoenzymes are
considered important in drug—drug interactions, the expansion
of research to specific CYP450 isoenzymes relevant for food-drug
interactions, such as aromatase (syn. CYP19A1, EC 1.14.14.1),
is a neglected issue in nutrition research. As phytochemicals are
currently recommended for breast cancer prevention and as add-
on accompanying aromatase-inhibitor pharmacotherapy, a fresh
look at the favorite mechanisms is needed.
The aim of this review is:
• To shed light on the link between non-communicable diseases
and underlying nutritional behaviors as well as on the
inheritability of metabolic performance and their impact on
these diseases
• To assess whether explanations beyond pure chemical
mechanisms of action are described in the literature and
whether a common interpretation based on genetic and omics
technologies is found.
METHODOLOGY
A semi-systematic online literature search was performed on
the platforms Medline R©, Sciencedirect R©, Embase R©, and Scholar
Google R© using mesh terms and keywords for several topics of
interest. The review strategies including the search and selection
of the articles are based on PRISMA guidelines for Systematic
1COST Action FA1403 (POSITIVe, https://www6.inra.fr/cost-positive).
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Reviews and Meta-Analyses (9). The studies were related to
the influence of nutrients on cytochrome P450 and how diet
can affect metabolic biochemical pathways. Information was
interpreted immediately. New keywords were defined for a step-
by-step incremental progress and reentered into the search
engines for a second and third run on each of the search chapters.
Firstly, basic search was performed on pharmacokinetics and
nutrients, substrates, inhibitors, inducers of human CYP450
isoenzymes, CYP19A1, aromatase, gender, pharmacodynamics
and targets of bioactive, food-drug interactions, nutrigenomics,
aromatase, and flavonoids. A literature research yielded 2954
bibliographic records in the first run with “[(breast cancer) AND
(cytochrome P450)]” keywords and 5307 with “(cytochrome
P450) AND nutrients.” Duplicates were identified and removed
from the pool of bibliographic records. Next, an accurate
screening of abstracts and titles was performed to determine
the most relevant articles. Afterwards, full articles were reviewed
using the following inclusion criteria: (1) studies which provided
information about the relationship between nutrition and breast
cancer; (2) studies which explained the metabolic pathways
of cytochrome P450 enzymes; (3) studies which explained
how some nutrients interact with substrates metabolized by
cytochrome P450 enzymes; (4) studies which provided clinical
information about the pathogenesis of breast cancer; (5)
studies which provided information about any cytochrome P450
enzyme. In conclusion, 52 studies were first retained, mostly
recent studies but also some earlier studies presenting analyses
that were not found in the most recent studies.
Secondly, the mechanistic pattern was semi-systematically
expanded to mechanistical explorations on specific enzymology
information about aromatase, breast cancer, breast cancer
associated to nutrition, cytochrome P450 associated to breast
cancer, nutrition and cancer, natural aromatase inhibitors,
risk factors for breast cancer, complementary therapies, and
breast cancer.
Thirdly, non-systematic specific search terms on
nutrigenomics and biochemical ascending and descending
pathways in the aromatase metabolism were searched.
Integration was approached in deductive reflection rounds.
Substantial bricks were assembled to a comprehensive nutrition-
relevant pattern of personalized nutritional medicine.
RESULTS AND INTERPRETATION
Pharmaco- and Nutrient-Kinetic
Considerations: Principles, Commonalities,
and Diversity of Gender- and Age-Related
Metabolic Capacity
From Bioactive to Effect—The LADME Processes
Medicines or foods will be either readily incorporated if
comparable to physiological substrates or metabolized for
elimination as xenobiotics. The processes of the passage of
xenobiotics across the intestinal wall, the body compartments
and organs until receptors are found, are qualitatively described
in the chronological kinetic steps Liberation, Absorption,
Distribution, Metabolism, and Excretion and in the dynamic
steps at the target/receptor as depicted in the Ariens Scheme
[(10, 11); Figure 1].
To cope with variability in these processes genetic approaches
have to be applied. Mutations on a single nucleotide (SNM,
single nucleotide mutation) results in a genotype diversity and
therefore different metabolic capacities, seen as polymorphisms
in a population. Polymorphisms are a frequent reason for
adverse drug events which increase in the case of polypharmacy.
The interaction risk for a combination of 2 drugs is 13%, for
4 drugs 38%, and for 7 drugs 82% (12). In-patients receive
5–7 drugs. Thus, pharmacokinetic considerations are crucial.
No estimation for food-food and food-drug interactions is
available although they seem to occur even more frequent
than drug-drug interactions. One of the reasons might be the
lower severity of incidences. The higher probability of food—
nutrient—drug interaction can be presumed by the vast amounts
of food ingredients and the higher number of hepatic isoenzymes
involved in this complex metabolism than in drug metabolism.
Ethnical groups show typical phenotypes. For instance, due
to a mutation on the gene coding for the CYP2D6 isoenzyme in
the Asian population, drugs being metabolized by this isoenzyme
contain only 50% of the dose used in Europe. This mutation is
important since many drugs (and possibly secondary nutrients)
are metabolized by CYP2D6. For nutritional substrates less data
and no interaction tables are available (13).
The objective of nutrigenomics research is to understand
how nutrients influence gene and protein expression and
why this expression varies between individuals. It is well-
known that even though individuals were to eat similarly,
some will become obese, others will develop cardiovascular
diseases, or allergies. A recent project aiming at promoting
research on interindividual differences has been adopted by the
governments of COST member countries (COST action FA1401:
“Interindividual variation in response to consumption of plant
food bioactives and determinants involved (POSITIVe), https://
www.cost.eu/actions/FA1403/#tabs|Name:overview)”1.
Evolution, globalization, and internationalization of
nutritional habits make genetic impacts slowly disappear
by genetic recombination and/or by adaption. Epidemiologic
assessments are more and more difficult to interpret since at least
in Western countries mixed populations lead to a recombination
of genetic codes. Otherwise, as foodstuff consumed is not only
produced in the consumers region as compared to times of
regionally dominated markets, but is rather of international
provenance containing new ingredients and components, genes
do not only determine how food is metabolized, but food acts
the other way around, i.e., by putting pressure on long-term
genetic and medium-term epigenetic adaption. This will lead
to new diagnostic tools such as genetic profiling and to novel
interventions on an individual level (14–23).
Bioaccessibility and Liberation of Bioactives
Flavonoid-remnants of processed flavonoid-rich foods show
various degradation patterns and quantities depending on the
excess steam and heat applied. Tomato ingredients seem to be
steam-volatile as Italian sugo for instance keeps more lutein, β-
carotene, and lycopene than steamed tomatoes. Long heating
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FIGURE 1 | Ariens Scheme. A substrate freely accessible from a medicinal product or from foodstuff is orally taken and passes the pharmacokinetic LADME steps
(liberation, absorption, distribution, metabolism, excretion). A part of the bioactive or xenobiotic may find in the pharmacodynamic step its targets such as receptors at
cell surfaces, cell nuclei, or circulating metabolites to yield an effect.
processes lead to degradation of anthocyanidins in blueberries
as only 3% remain after blueberry jam production. Precious
Mungo sprouts components (genistein, daidzein) are fairly well-
conserved by gentle roasting. Green tea macerated in 80◦C water
for 3min keeps higher bioactive contents than when extracted at
hotter temperatures (24).
Absorption and Distribution
Absorption of nutrients and xenobiotics is mainly an
individualized procedure depending on a human being’s
metabolic capacity. This in turn varies with age, gender,
ethnicity, and inherited metabolic performance. Gastric tube’s
morphology and physiological function shows major gender
differences. In men the mean gastric fasting pH is 2.15 whereas
it is situated between a range of 2.5 and 2.8 in women. This is
a nearly 5-fold higher acidity in a male stomach and explains
the higher prevalence of duodenal ulcers in men. A sufficiently
acidic pH below 3.5 is determinant for the activation of pepsin
from its precursor pepsinogen, duodenal secretin stimulation (at
pH 4.0–4.5), and pancreatic enzymes’ release as well. Gastric and
intestinal liquid differ in volume (bigger in men), in emptying,
in gastrin and bicarbonate concentration, and in colon transit
times (shorter in men). Female hormone regulation by estrogens
and progesterone is depressing gastrointestinal motility in
women especially in pregnancy. Endocrine secretion in women
is triggered when nutrients are provided and not permanently
as compared to men’s endocrine secretion and growth hormone
release. Acidity at this upper GI tube is increasing from the
fasting pH of 2–5 to pH 1.7 immediately after a meal intake and
dropping to pH 4.3 toward the end of the digestion procedures
after 2–3 h. As a summary, absorption is “quantitatively and
qualitatively influenced by gastrointestinal pH and by intestinal
motility” (12). On the other hand, absorption of precious
nutrients is substantially decreased by tannins from tea or coffee
due to precipitations (25).
For pepsin activation, which depends on a pH <3.0–3.5, and
bactericidal effect, higher gastric pH of women would do as well.
However, the gastrointestinal milieu changes fundamentally pH
permanently to >4 both upon medication with antacids such as
proton pump inhibitors (PPIs) and as a result of aging.
Drug or nutrient availability does not depend only on
active carrier driven transports, but also on diffusion. Long-
term PPI treatment switches the stomach’s function almost
permanently off. The underlying pH change has consequences
for the solubility and therefore for the bioavailability of a
important number of micronutrients such as vitamins C, B12,
folate, and oligo-elements such as zinc, iron, magnesium,
and calcium, and even of medicines such as ketoconazole,
itraconazole, atazanvir, cefpodoxime, cinnarizine, enoxacin,
dipyridamole, various oligoelements, or ascorbic acid, which
are less bioavailable, and of nifedipine, digoxin, penicillin,
erythromycin, or alendronate, which are more bioavailable
(26–31).
Transport across the membranes and thus efficacy depend
dramatically on gastrointestinal pH conditions. These transports
may be bidirectional. Whether or not non-dissociated or
dissociated substrates will be more readily absorbed depends on
the absorption mechanism and the similarity to physiological
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molecules (passive diffusion, carrier-mediated transport, etc.).
An important membrane-bound transporter at the apical side
of enterocytes and at many other membranes, e.g., liver
and blood-brain-barrier, is the P-glycoprotein (P-gp). P-gp is
multi-drug-resistance1-Gene (MDR1) which builds an efflux of
xenobiotics out into the lumen. It is often co-localized with
CYP3A4,5,7 isoenzymes., For the P-gp substrates, just as for
these isoenzymes, inhibitors and inducers can be distinguished
(12, 25). pH is not only determinant for absorption of
nutrients, but also for non-nutrient substrates, e.g., allergens
and other xenobiotics such as non-steroidal-anti-inflammatory
drugs (NSAIDs) or benzodiazepines. These xenobiotics have
rather low pKa values. Their absorption by passive diffusion
therefore needs acidic pH conditions for absorption from the
upper GI tube and treatments with antacids such as PPIs
are likely to inhibit the quantitative absorption of NSAIDs or
benzodiazepines and result in clearly lower anti-inflammatory
effects (32).
Carbonates as antacids currently used in single doses beyond
1 g, “will have an onset of about 6min and a time with pH values
over 3.0 of about 2 ½ h.” Ranitidine, meanwhile obsolete as H2-
antagonist, was used for reflux in doses of 75mg which led to
an onset of 65min. Its effect was rather unreliable and lasted
for 36min to 13 h (33). As a comparison, today’s favorites and
blockbusters pantoprazole and esomeprazole (both used in daily
doses of 40mg) yield a median 24 h pH of 3.7 vs. 4.7 in the steady
state after 5 days. Long-term treatments with esomeprazol and
pantoprazole have antacid effects of keeping gastric pH over 4
for 16.1 and 10.8 h, respectively. The long half-life times of these
PPIs cannot be antagonized by any antidot. pHmust in situations
of need be imitated by ingestion of acidic beverages. Restoration
ad integrum of the proton pump by de novo biosynthesis
of the H+K+-exchanging ATPase will last several days. “The
production half-life is approximately 50 h” (34–38).
Digestion-resistance during gastrointestinal transit is an
important feature of food allergens. This resistance is supported
by antacids, e.g., PPIs. A particular risk is arising for elderly
patients suffering from gastroenterological diseases, tumors, and
infections and consuming regularly “crustacean, eggs, fish, milk,
peanuts, soybeans, tree nuts or fruits, and wheat.” In addition,
with the loss of gastric acidity, the antibacterial intestinal activity
becomes ineffective. Therefore, a net risk of “bacterial overgrowth
of Clostridium difficile, Campylobacter jejuni, and Salmonella
ssp.” is emerging. “This is also true for the inflammation,
ulcer, and stomach cancer associated Helicobacter pylori which
produces big amount of urease leading to a shift in gastric pH
from between 2.2 and 2.8 to a range of 6–7” (39–42). There
is a strong correlation between PPI treatments and “various
pathologies such as lactose intolerance, celiac disease, atrophic
gastritis, rheumatoid arthritis, and/or diabetes mellitus” (43–
46). It is highly important to consider the consequences of
pH increase on absorption of micronutrients, mainly iron,
copper, and further co-factors of essential enzymatic metabolic
reactions. Whereas, B-vitamins are co-enzymes in pyruvate
decarboxylation and citric acid cycle, iron and copper are needed
in the oxidative phosphorylation (respiratory chain) as part of
some of the five enzyme complexes and as prosthetic group
in hemoproteins.
Absorption of such oligo-elements follows the rules of
solubility of aqua-complexes which is in turn dramatically
depending on pH. The example of iron aqua-complexes shows
that at pH conditions encountered at the jejuno-duodenal
junction, where pH raises steeply, iron becomes less soluble
as a result of a sequence of deprotonations of its aqua-
complexes from a 3- or 2-fold positively charged to an uncharged
insoluble complex in both cases of ferric iron and ferrous iron:
(32, 47–49).
[Fe(H2O)6]
3+ -> [Fe(H2O)5(OH)]
2+ +H+ (pKa 2.2)
[Fe(H2O)5(OH)]
2+ -> [Fe(H2O)4(OH)2]
+ +H+ (pKa 3.5)
Fe(H2O)4(OH)2]
+ -> [Fe(H2O)3(OH)3]
0 +H+ (pKa 6.0)
[Fe(H2O)6]
2+ -> [Fe(H2O)5(OH)]
+ +H+ (pKa 6.74)
[Fe(H2O)5(OH)]
+ -> [Fe(H2O)4(OH)2]
0 +H+ (pKa 9.5)
These mechanisms lead to iron precipitates in the course of the
passage along the GI tube starting to be relevant from about pH
3 upwards (Figures 2A,B). Precipitates are composed of colloidal
and amorphous ferric iron hydroxides. Condensation is triggered
by deletion of water out of the complexes and formation of
hydroxo bridges. It is obvious that that such an amorphous mass
cannot be absorbed from the GI tube.
Anemia caused by iron deficiency is treated more successfully
by medicines containing ferrous iron Fe(II+) as an active
ingredient, because the main loss of the alternative ferric iron
would result close to the junction of duodenum to jejunum when
within 10 cm distance alkaline conditions become predominant.
Remaining ferric iron may be reduced in the distal duodenum to
its ferrous form [Fe(H2O)6]
2+. Ferrous condensates form only
at alkaline conditions. This is the reason why ferrous iron is
absorbed more readily than ferric iron which is at these pH
conditions already precipitated and lost for absorption. It is wise
to supply iron dissolved in fruit juice such as orange juice due to
ascorbic acid contributing to the stabilization of better absorbable
ferrous iron, increasing the absorbed amount up to 3-fold. The
role of ascorbic acid contained in fruit juice is to enhance acidic
conditions in the absorption region in case of PPI treatment and
to reduced ferric to ferrous iron. The repeated supply of smaller
amounts of oligoelements is more likely to lead to an efficient
absorption and distribution thanwith high loading doses. Copper
and cobalt but not manganese and zinc aquo-complexes suffer
as well from partial loss when pH conditions are unfavorable for
absorption (32, 47–49).
Depending on age, gender, physical activity and many more
factors, the ratios of body compartments vary and therefore the
distribution according to the hydrophilic—lipophilic profile of
a substrate.
Ontogeny, peri- and post-natal phase, adaption, lactation
Availability of active pharmaceutical ingredients is particularly
low in newborns as metabolizing enzymes in the liver are most
active after birth and declining when age increases. Not only
activity but also inducibility is highest in newborns. However,
post-natal inducibility is lower than in the embryo stage. Peaks
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FIGURE 2 | Absorption and bioavailability of iron. “Free” iron exists in aqueous solutions as aquo-complexes and is therefore an acid which deprotonates step by
step. It solubility depends on its oxidation state and pH. (A) Precipitation of iron-(III)-aquo-complexes starts already at fairly acidic conditions. This leads to a loss of
solubility decreasing from the acidic environment in the stomach and the proximal parts of the duodenum. An amorphous mass once precipitated cannot be absorbed
from the GI tube an more. (B) Precipitation of iron-(II)-aquo-complexes are becoming critical only at neutral an alkaline conditions. Ferrous iron condensates only at
such conditions. This is the reason why ferrous iron is absorbed more readily than ferric iron which is at these pH conditions already precipitated. Ferrous iron is
therefore suitable for iron-anemia treatment.
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are observed before birth (50). For this stage of ontogeny and of
neonatology, no information about a gender impact nor about
ethnical variability is available.
Full peptic digestion capability develops after 2 years only,
whereas antisepsis due to low pH in the stomach is immediately
built up after birth: “In full-term babies, gastric acidity changes
within 1 h from 6.1 to 5.4, within 2 h to 3.1, and within 6 h to 2.2.
pH increases afterwards for 10 days and goes down again only
slightly. Acid output similar to adults is reached by 24 weeks. pHs
were measured either by potentiometry or by titration in older
methods (51–54). Results should be equally reliable with either
one of themethodologies of measurement. “Pre-term born babies
have a gastric pH >4 for 80–90% of time, the acidity only rising
with age” (55).
Bottle-fed babies have a similar gastric pH to breast-fed babies.
“An increase in gastric pH to around 4.0 is observed for infants
between 1 and 12 months with chronic diarrhea and protein
malnutrition, combined with bacterial overgrowth essentially
with Gram-negative bacilli, in 57% of the cases. The bacterial
overgrowth happens at the moment of the evolution of the
disease to a chronic state. Breast-fed babies do not have bacterial
overgrowth of gram-negative bacilli and no diarrhea” (56). This
bacterial overgrowth is favored by bottle-feeding with formula
products, as immunoglobulins from lactatingmothers and timely
physiological pH adaption are lacking. In addition, children aged
4–36 months suffering from GERD (gastro-esophageal reflux
disease) and treated with H2 antagonists or PPIs for 8 weeks
showed a higher risk for acute gastroenteritis and pneumonia,
although otherwise healthy. These risks persist after stopping the
therapy (39).
Childhood
Prepubertal childhood. There is a gender difference in
prepubertal oligo-element absorption: In the fasting state, male
preadolescents absorb 35.2% and female preadolescents 45% of
an iron loading dose. As supplement in a meal, preadolescent
men absorb 14.8% and preadolescent women 24.7% of a dose.
Serum ferritin differed only marginally in this study. As a result,
iron anemia is as high as 12.1% in boys aged 11–15 and only
6.1% in girls of the same age (57).
Pubertal childhood. Hormonal biosynthesis and changes all
over life is mirrored not only by body morphology, but also
by the extra-hepatic regulation of metabolic processes. The
breast consists of differently developed lobes and is equipped
with the adequate CYP isoenzymes such as aromatase to
locally biosynthesize steroids from circulating precursors. These
hormones are liberated and systemically measurable. Estradiol
and progesterone bind to their receptors ERα, ERβ, PR A, and
PR B and initiate the cell signaling cascade finishing up in the cell
nucleus. Estrogens induce the ductal development, progesterone
the lobes and alveolus. Type 1 (65–80%) and type 2 lobes (10–
35%) predominate in child-less women. Type 3 dominates (70–
90%) in women after delivery. In the menopause, involution
occurs, and type 1 dominates again. Risks for breast cancer are
an early menarche, a late menopause, and a higher age at the first
pregnancy. A protection is evident from an early pregnancy and
delivery (58).
Adulthood
Ovulation-suppressed women. Apart from iron, another
important co-factor of enzymes is copper. In the age group of
20–59 years old persons, its absorption is generally higher in
women (71%) than in men (64%). This difference disappears
later in life at the age between 60 and 83 years. Copper and
ceruloplasmin plasma levels of women aged between 20 and 39
years taking ovulation suppressors tend to be higher than in
women with physiological cycles (59).
Estradiol suffers from an extensive hepatic first-pass effect.
As a result of its low bioavailability of <10%, its derivative
Ethinylestradiol is the most widely used estrogenic component
of combined oral contraceptives. The absorption process differs
individually in length (1–2 h), extent (generally around 90%
bioavailability), and the time for reaching the maximum peak
of blood level (1–2 h mostly, with observed lag times of
up to 6 h). Steroid concentration in the portal vein blood
after absorption and hepatic first-pass is still 25–65% of
the amount ingested and has an effect on several globulins
such as thyroid binding, sex hormone binding, corticosteroid-
binding globulins, angiotensinogen, as well as coagulation and
fibrinolytic factors. 2-hydroxylations by CYP3A4 and CYP2C9
dominate with wide individual variation, whereas 4-, 6-,
16α-, and 16β-hydroxylations are compromised to physiological
estradiol. Besides glucuronidation, sulfate-conjugates at positions
3 and 17 are readily built and are 10-fold more concentrated
in the circulation than ethinylestradiol itself. Partially, to
11 and 21%, respectively, the sulfates are deconjugated to
ethinylestradiol during enterohepatic recirculation. Plasma
levels of ethinylestradiol differ markedly between ethnic
groups. Highest plasma levels were found in Nigerian women,
lowest in women from Thailand. Nigerian women excreted
mainly conjugates of ethinylestradiol and hardly any oxidation
derivatives (58).
Progestins used for contraception and/or post-menopausal
hormone replacement therapy vary widely in structure,
absorption and metabolism. Large inter- and intrasubject
variability is observed. The Cmax is reached within 1–3 h. Plasma
levels are between 70% and more than 90%. T1/2 differs from
between 8 and 12 h for norethindrone and dienogest to between
50 and 80 h for cyproterone acetate (60).
Obesity is considered an inflammatory disease with elevated
levels of some cytokines such as IL-6 and TNF. Cytokines are
known as transcriptional regulators of the CYP450 expression.
In addition, fatty livers might affect the function of hepatic
isoenzymes. A decrease of activity is reported for CYP3A4,5,7
and CYP2E1, whereas the efflux transporter P-gp is expressed
higher. Although CYP450 isoenzymes’ activity decreases and
conjugation increases, the “one dose fits all” approach is
applicable in both obese and normal weight women, as
oral contraceptives influence the hypothalamic—pituitary—
ovarian axis and the feedback loops similarly with a tendency
toward more follicle maturation in obese women (60). A
higher part of hormonal contraceptives is distributed toward
the fat mass in obese subjects. This bears a higher risk
of hormonal contraceptives failure as contraceptives’ plasma
levels decrease. However, no difference in distribution volumes
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of ethinylestradiol and levonorgestrel between normal and
obese BMI subjects could be demonstrated. Instead, the time
to reach the levonorgestrel steady-state was found to be
adversely affected by obesity and the half-life in obese subjects
was twice as long. While peak levels of oral contraceptives
(ethinyl estradiol and levonorgestrel) are somewhat lower in
obese women (BMI 30.0–39.9) compared to normal weight
women (BMI 19.0–24.9), the through levels over the cycle are
similar. The small pharmacokinetic differences do not activate
ovarian follicles (61).
Pregnancy. “As a result of hormonal changes, pregnant women
often suffer from heartburn induced by reduced esophageal
sphincter pressure and heartburn due to sex hormones,
essentially progesterone” (62). “In this patient group, short-term
acid neutralizers or H2-antagonists should be preferred instead
of PPIs in possibly meal-free phases in order to omit the risk
of incomplete protein digestion and the risk of predisposition to
immune responses of the child. This risk is indeed confirmed in
a Swedish study correlating the incidence of allergy and asthma
of babies with anti-ulcer consumption of their mothers during
pregnancy.” The allergy incidence of the discharged children was
5.03%. This significance was shown by an odds-ratio (OR) of 1.43
with a 95% confidence interval (1.29–1.59). The development of
childhood asthma is higher in exposed children (5.6%) than in
the population (3.7%), statistically validated by OR 1.51, 95% CI
1.35–1.69 (63).
Metabolism
To cope with food-derived interaction variability, all 57
CYP450 isoenzymes should be assessed. In addition to
pharmacotherapeutically relevant CYP450 isoenzymes such
as those listed in the Flockhart tables (64), substrates, inhibitors
and inducers originating from food, e.g., anthocyanidins,
flavonoids, vitamins A, B1, B2, D, E, brassica species (broccoli,
Brussel sprouts, cauliflower), chargrilled meat, tobacco, ethanol,
St. John’s wort, grapefruit juice, or Cassia (Chinese) cinnamon,
and many more have to be of interest to nutritionists and
nutritional medicine. In clinical nutrition, not only deficits
are challenging, but too much intake as well. Well-known to
endocrinologists were the goiter inducing brassica factors of
mustard oil glycosides from brassica species. This effect was
triggered by thiocyanate liberated and competing with iodine for
the thyroid peroxidase catalyzed iodination of thyroglobulin (65).
Metabolic reactions are predominantly assumed by the
cytochrome P450 superfamily. P450s are present in Homo
Sapiens, and over 4500 individual members are known in all
living species. “450” relates to the Soret region in the absorption
spectra of these enzymes where their λmax are located. CYP450s
are classified into 18 families and 43 subfamilies. Apart from gene
expression and the phenomenon of polymorphism, gender and
age have an impact on the activity and thus on inter-individual
variation. Members of the families CYP1, CYP2, and CYP3 are
polyvalent and therefore suitable for metabolic transformation
of a large number of drugs and structurally diverse xenobiotics,
whereas the families CYP11, CYP17, CYP19, and CYP21 tend
to have only a few substrates, predominantly their physiological
substrates, i.e., steroid hormones, and to be therefore highly
specific (66). This enzymatic polyvalence is clinically important
mainly for toxicological reasons. However, these enzymes may be
saturated and become rate-limiting pacemakers. Substrates may
accumulate and adverse side effects may arise from increasing
blood levels of the substrates. Inhibition may be established
within a few days. Induction develops more slowly, in general
within some weeks (12).
Metabolism is discussed mainly in terms of the hepatic part
due to its predominance, although it happens also in extra
hepatic hormone dependent tissues, e.g., CYP2S1 in epithelial
tissues, mainly skin, but also kidneys, intestines, lungs, nasal
epithelium. This is the reason why efficacy of pharmacotherapy
may depend on target tissues, e.g., retinoids in skin. Hepatic
and intestinal P-gp and other transporters are expressed to a
higher degree in men than in women. In men, some isoenzymes
have a higher activity, due to induction, e.g., CYP1A2, CYP2C9,
CYP2E1. CYP1A2 can be induced to be 40 times as active in
case of a high charcoal-grilled meat consumption. In women,
some CYP450 isoenzymes are more expressed than in men,
e.g., CYP3A4,5,7 as a function of the menstrual cycle with top
level before ovulation and in pregnancy, CYP2A6, CYP2B6,
or CXP2D6, which is highly expressed only in the fertile
phase, CYP3A4,5,7.
Inconsistent data seem to arise from cross-influences of P-
gp and CYP3A4,5,7. The efflux glycoprotein and the CYP450
isoenzymes are co-localized. Thus, in clinical studies evaluating
both transporting P-gp and metabolizing CYP3A4,5,7 care has to
be taken to omit confounding (25). Research on nutrients in this
domain is scarce and remains to be established. The reasonmight
be a lack of using histological and cell-biological methodologies
in nutrition research as compared to in vitro human liver
models currently used in pharmacological and pathological
research (11).
Biochemistry of cytochromes P450
Cytochrome P450 isoenzymes are tetramethylated hemoproteins,
such as cytochrome c, ferriprotoporphyrin IX, hemoglobin,
or myoglobin, with iron (+III) as central atom, and widely
distributed throughout the biological world. From 1980,
CYP450’s crystal structures were solved for 54 unique structures
(67). Subtle changes from one molecule to a closely related
one generally lead to drastic changes in behavior, i.e., to
different groups of hemoproteins such as monoxygenases (=
mixed-function oxygenases), peroxidases, peroxygenases, and
oxygen carriers. Typical enzymatic cycles and intermediate
compounds involved provide highly reduced oxygen derivatives
as an oxidant (Figure 3). However, CYP450 isoenzymes do
not only act as monooxygenase to detoxify. Today’s knowledge
hints at a more complex role in regulation on hepatic and
extra-hepatic tissues.
The central iron atom of hemoproteins carries oxygen in
different oxidation states, i.e., as reactive oxygen species which
either oxidize substrates of the enzymes compounds I and
II by 1 e− or 2 e− donations, respectively, or contribute to
irreversible enzyme inactivation in case of excess substrate by
the enzymes compound III. Inactivation of the enzyme occurs
by cleaving the heme moiety and liberating iron which in turn
Frontiers in Nutrition | www.frontiersin.org 8 April 2020 | Volume 7 | Article 37
Jenzer and Sadeghi-Reeves Nutrigenomics Impacts on Aromatase Function
FIGURE 3 | Oxygen Chemistry. Dioxygen itself exists in its ground state as biradical. This is the reason why only the existing partial pressure is healthy to mankind and
hyperbaric atmosphere would be toxic. Free radicals derived from successive 1-e− reductions of dioxygen may be harmful to many organic molecules at physiological
conditions. Oxygen derivatives are indispensable intermediates in oxidoreductase reactions such as detoxifications, hydroxylations, peroxidations.
contributes to Fenton-like reactions producing highly oxidative
hydrogen radicals:
Fe2+ +H2O2→ Fe
3+ + OH. + OH−
Copper may substitute for iron. It yields an even faster
production of hydroxyl radical (65).
Monooxygenation require NADHP and O2 (Figure 4A):
RH+ O2 + NADPH+H
+→ ROH+H2O+ NADP
+
To bind dioxygen, the prosthetic groupmust be reduced from the
ferric to the ferrous state by a first 1-e− transfer from NADPH.
Another 1-e− transfer from NADPH induces a structural
rearrangement of the high electron-density on the pi-system and
the shift of the density on the dioxygen which leads to O-O bond
cleavage. One of the oxygens is liberated and protonated to form
water. The remaining oxygen is configured as highly reactive
ferryl intermediate (Fe = O). This ferryl intermediate obtains a
hydrogen atom from the substrate RH. After the hydrogen release
the substrates forms a radical intermediate which in turn captures
the preformed hydroxyl group from the enzyme intermediate to
form the hydroxylated substrate. The release of OH brings iron
back to the ferric state (68). Thus, one of the oxygen of dioxygen
will end up as hydroxyl function in the substrate. The second
oxygen atom will be reduced to water.
Mono-oxygenation can be performed by a peroxide shunt as
an alternative. Single oxygen donation from substrates such as
peroxides lead to the shortly living and hardly detectablepi-cation
radical compound I. This shunt resembles to a peroxidative
cycle as depicted for lactoperoxidase (LPO) (Figure 4B). In
peroxidases, the catalytic cycle of P450 isoenzymes starts on
binding the substrate, seen as a spectral change. e− source
is NAD(P)H via cytochrome P450 reductase. The reduction
equivalent of iron is situated mainly paired in d-orbitals to
yield the low spin ferrous state. Molecular dioxygen is bound
covalently. Another e− transfer reduces the dioxygen adduct,
which is rapidly twice protonated, and liberates water. The
resulting intermediate correlates to the highly reactive pi -cation
radical compound I which catalyzes any further reaction, e.g., a
hydroxylation. From compound I upon release of the product,
the enzyme reconverts to the resting state (70). The normal
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FIGURE 4 | Outline of the catalytic cycles of oxidoreductases. (A)
Hydroxylation of substrates of aromatase requires the activation of oxygen.
This activation is promoted by the heme prosthetic porphyrin ring system. An
electron transfer reduces the ferric to the ferrous intermediate state, which
enables iron to bind dioxygen. Another electron transfer induces a
rearrangement of the highly electron-dense pi-system and cleavage of the O-O
bond. One of the oxygens is protonated and liberated as water. The remaining
oxygen is configured as ferryl intermediate which extracts a hydrogen atom
from the substrate. A transient radical of the substrate thus formed captures
the OH group from the enzyme intermediate to end up as hydroxylated
substrate. With the permission of Berg et al. (68). (B) Pathways in
lactoperoxidase-catalyzed H2O2 metabolism. I
− reacts with compound I by
direct 2e− transfer. The normal peroxidatic cycle includes ferric
lactoperoxidase -> compound I -> compound II -> ferric lactoperoxidase.
H2O2 in excess leads to formation of compound III and reconversion to the
resting enzyme via the ferrous state. Compound III pathway is combined with
irreversible inactivation of the enzyme. The conceivable structures of the heme
moieties of lactoperoxidase’s ground state and intermediate enzymatic
compounds show a movement of iron out of plane (not depicted) (65, 69).
peroxidatic cycle includes ferric lactoperoxidase -> compound
I -> compound II -> ferric lactoperoxidase. H2O2 in excess
leads to formation of compound III and reconversion to the
resting enzyme via the ferrous state. Compound III pathway is
combined with irreversible inactivation of the enzyme (69). The
heme moieties of lactoperoxidase’s resting ground state and of
its intermediate compounds are characterized by the conceivable
movement of iron out of plane which impacts solubility and
reactivity (65).
Excretion
As absorption and excretion sum up to a typical Bateman-
shaped curve representing the plasma level of a single dose,
there is a complex interrelation and regulation of biochemical
pathways. Isolated views lead to erroneous interpretations
of pathophysiological situations. A typical example is the
assessment of the impact of salt intake on the highly public-
health-relevant hypertension. Both excess and insufficient supply
of sodium are recognized as inductors of non-communicable
diseases. However, this does not yet qualify only intake nor
excretion as the only reasons of hypertension. The question is
rather what comes first, overconsumption of unhealthy foodstuff
as inductor of cardio-vascular deterioration followed by manifest
diseases, or rather the other way around, i.e., heart and kidney
insufficiencies followed by the inability to excrete sodium
efficiently. So far, not enough evidence has been presented for
neither one of the two theses. It is likely that individual histories
differ. Corresponding clinical studies suffer almost generally
from systematic errors such as biases and confounding factors
as well as unprecise exposure and outcome conditions. A study
claiming that BMI is the main contributory modifiable factor of
blood pressure level included in a meta-analysis 8,670 volunteers
from a network-questionnaire on age-adjusted associations of
hypertension and life-style. The questionnaire included a 3
times 24 h recall of dietary intakes. The outcome was a claim
of hypertension being associated with elevated BMI, age, and
education and of salt not being associated with systolic blood
pressure in either sex after multiple adjustments (71). Another
study did not find a hypertension lowering effect of low sodium
intake in a particular regional study (72). The contrary claim
that salt reduction lowers blood pressure was issued as a result
of a meta-analysis including 3,220 participants in 34 trials.
These participants reduced their daily salt consumption to 4.4 g
for 4 weeks. The results reported and interpreted included a
reduction of systolic blood pressure of −4.2 to −2.1mm Hg
over all, of −5.4 to −2.8mm Hg in hypertensive participants,
and of −2.4 to −1.0mm Hg in normotonic participants (73).
These marginal changes do not seem to be highly reliable. They
contribute to implausible results in human nutrition research
(4, 7). It is advisable to issue no claim at all actually due to
insufficient proofs from both observational and experimental
studies (74):
• Blood pressure changes reported are modest and variable
• Effect seems to be more distinct in the elderly and in subjects
suffering from higher blood pressures
• There is no evidence that a salt intake reduction is safe
or cardioprotective
• There is no comparison of cardioprotective, safe, efficacious,
and economical medicines indicated in hypertension
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FIGURE 5 | Mechanism of the aromatase-catalyzed enzymatic biosynthesis of 17β-estradiol from its androgenic precursor testosterone. The α,β-unsaturated ketone
of ring A of the steroid is transformed to a phenolic structure. The biosynthesis consists of three consecutive reactions, two hydroxylations followed by a C-C bond
cleavage.
• There is no convincing outcome assessment focused on
the length and quality of life that would justify a public
health recommendation to a whole population rather than
to a selection of individuals in the context of personalized
nutritional medicine
Pharmaco- and Nutrient-Dynamic
Considerations
Steroid Metabolism, Aromatase, Estradiol Receptors,
and Breast Cancer
CYP19A1, syn. Aromatase, is the CYP450 isoenzyme catalyzing
the transformation of testosterone and androstenedione to
estrone and estradiol. The enzymatic reaction consists of a
concomitant demethylation and sterol ring A aromatization
starting with two conventional hydroxylations yielding the 19-
hydroxymethyl derivative of the substrate and a 19-gem-diol,
which rapidly decays to an aldehyde. This one is cleaved
at the C-C bond at C19 yielding formic acid which has
incorporated both oxygens enzymatically frommolecular oxygen
(75). The monooxygenation is depending on the activation of
molecular oxygen in CYP450 isoenzymes [(76); Figure 5]. The
catalytic site in vivo consists of iron chelated as porphyrin
derivatives. Nitrogen compounds replacing porphyrin as chelator
are interesting candidates in chemical in vitro research as reaction
kinetics differ markedly. Such candidates are deferiprone,
deferoxamine, deferasirox (77).
The main targets of medicines indicated in breast cancer
are aromatase (by aromatase inhibitors, e.g., tamoxifen) and
selective estrogen receptors (modulated by selective estrogen
receptor modulators SERMs). 17β-estradiol (E2) is the most
biologically potent estrogen in breast tissue. However, breast
cancer and highest E2 blood levels are not directly correlated.
Most women develop breast cancer after the menopause. In
this phase of life, remaining E2 plasma levels are 10 times
lower due to ovarian exhaustion. Thus, the uptake of E2 from
ovarian biosynthesis via blood stream into the mammary gland
is unlikely to be responsible for local estrogen concentrations
in breast tumors. Another mechanism must be the causation
of neoplasms. It is more likely that “hot spots” of aromatase
become highly active to increase the intra-tumor biosynthesis of
estrogens from the precursors testosterone and androstendione
circulating in the plasma (58, 78). Thus, the neoplasm itself
induces a local production of aromatase which increases
in turn the effectiveness of therapeutically and preventively
used aromatase inhibitors. Apart from CYP19A1, a mixed-
function monooxygenase, tumorigenesis has been explained as
an effect of lactoperoxidase present in the mammary glands, a
peroxidase, oxidizing estrogens at the 3-hydroxylgroup to free
radicals (79).
Aromatase inhibitors are the therapy of choice for most post-
menopausal breast cancer patients. It may be accompanied by an
adjuvant therapy with aromatase inhibitors from plants. Alone,
these aromatase inhibitors from plants are suitable to contribute
for long-term breast cancer prevention [(13, 24); Figure 6].
However, enhancement or reduction of the enzyme activity or its
protein expression by food ingredients is an understudied issue.
There are a couple of structure requirements substrates should
fulfill in order to interact with aromatase to exert an activity,
either an effect or an inhibition (77, 80):
• α-/β-unsaturated ketone function
• This provides a flat configuration. Therefore, an aromatic ring
system is also suitable
• Z-conformation at the double bond
• An asymmetric center (∗C, spiro, chock, or ansa
configuration in position γ to the ketone) wearing
a methyl substituent. Testosterone is according to
IUPAC rules (1S,2R,10R,11S,14S,15S)-14-hydroxy-2,
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FIGURE 6 | Aromatase and aromatase inhibitors. Estradiol and estrone are enzymatically biosynthesized by aromatase (CYP19A1) from androgenic precursors.
Aromatase inhibition is the current pharmacotherapy and suitable prevention of breast cancer. There are more than 30 enzymatic reactions upstream, downstream,
and sidestream of the aromatase reactions. Therefore, an delicate equilibrium in the hormonal status is highly regulated and fine-tuned.
15-dimethyltetracyclo[8.7.0.0∧{2,7}0.0∧{11,15}]
heptadec-6-en-5-on
• Steroid binding site located on the apoprotein
• The aromatase substrate must fit into this 3D-structure.
Flavonoids as Inhibitors of Estradiol’s Action
Aromatase is a target of flavonoid bioactives. Flavonoids’
3-dimensional partial structure ressembles the physiological
substrates of aromatase, i.e., testosterone and androstenedione.
Flavonoids compete therefore for aromatase and enhance
or inhibit modulators of 17ß-estradiol receptors ERα and
ERβ. The inhibitory effect on the enzyme needs a structural
relationship between androstendione or testosterone and a
partial structure of flavonoids (Figure 6). As a result, inhibitors
and natural substrates compete for the enzyme and antagonize
the transformation of the physiological substrates to estrogens.
The mechanism of action of flavonoids is currently described as
antioxidative effect. In fact, as the oxygen cannot be transferred
from the enzyme’s intermediate compound to the substrate
but to the competing flavonoid, this explanation is in line
with the competitive antagonism explanation and the classical
pharmacological interaction concept.
Aromatase inhibitor stereochemistry and quantitative
conditions at the target are essential to determine the effect it will
have on the development of breast cancer.When using aromatase
inhibitors, estrogen levels decrease in the plasma and locally in
breast “hot spots,” decreasing the outbreak or progression of
breast cancer. In addition to the pharmacochemical aromatase
inhibitors, there are many natural components that can perform
the same action, eventually with fewer adverse effects (81).
Inhibitory effects on aromatase have been described for
many plants, mostly containing polyphenols/flavonoids [(82–84);
Table 1]. The most popular plants are:
• (Green) tea and soy intake as a result
of the active principles caffein, calcitriol,
ellagitannins, flavonoids/polyphenol/isoflavones
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TABLE 1 | CYP19A1 active food ingredients, their targets, and effect on the
enzyme: Substrate (S), Inhibitor (–), Inducer (+).
Plant and active ingredients Targets Effect on
aromatase
Allium species, containing allicin, S-allyl
cysteine, S-allyl mercaptocystein,
organosulfides (diallyl mono-, di-, trisulfide)
• A. sativum = Garlic
• A. ursinum = Wild garlic
Cell signaling
Glutathiontransferase
Apoptosis
–
Brassica species [Cruciferous vegetables
(mainly sprouts)], containing indole-3
carbinol, organosulfides, sulpharophanes,
isothiocyanate from glucosinolates
• Broccoli
• Brussels sprouts
• Cauliflower
• Kale and bock choy
Aromatase
Cell signaling
Glutathiontransferase
Angiogenesis
VEGF receptor
NF-κ B
Apoptosis
–
Citrus spp., containing prolin, betain,
naringenin, monoterpenes, D-limonene
• Grapefruit
• Orange
• Mineola
Aromatase
COX-2
Cell signaling
–
Coffee, containing melatonin, and
melanoidins
Aromatase
COX-2
Cell signaling
Metabolic
regulation
–
Curcuma domestica and C. longa (Turmeric),
containing curcumin
COX-2
ROS scavenging
–
Fruits (pigmented) and berries, containing
ellagitannin, ellagic acid, sitosterol,
anthocyanidines (delphinidine, myrtillin),
phenolic acids
• Urolithin B in pomegranate,
• Rubus ssp.: lambertianin C in
blackberries, sanguinin H-6 in
raspberries, myrtillin in blackcurrant
pomace
• Fragaria × ananassa Duch.: agrimoniin)
Aromatase
COX-2
Cell signaling
Glutathiontransferase
Angiogenesis/VEGF
NF-κ B
Apoptose
–
Ethanol Aromatase +
Fatty acids from animal or vegetable oils
• ω-3 fatty acids
◦ docosahexaenoic acid
◦ eicosapentaenoic acid
• ω-6 fatty acids (linoleic acid)
• Fish-oil
Nuclear receptor
Anti-oxidation
–
Grape seed, containing resveratrol Aromatase
COX-2
ROS scavenging
–
Green Tea, containing
(–)-epigallocatechingallate
Aromatase –
Honey, sugarcane molasses containing
melatonin and melanoidins
Aromatase
COX-2
Cell signaling
Metabolic
regulation
–
Liquorice (Glycyrrhiza glabra), containing
glycyrrhizin, Glycyrrhic acid
Aromatase +
Mushrooms
• Agaricus bisporus (= white or brown
button, baby button, portobello, crimini,
champignon de Paris)
Aromatase –
(Continued)
TABLE 1 | Continued
Plant and active ingredients Targets Effect on
aromatase
• Lentinula edodes = Agaricus edodes (=
shiitaki, Chinese black mushroom,
golden oak mushroom)
Nuts, containing fatty and amino acids (e.g.,
arginine)
• Walnut
• Hazelnut
• Cashew
Nuclear receptor
VEGF receptor
–
Soy, containing phytoestrogens, stilbenes,
and genistein
Aromatase –
Testosterone (and Androstenedione) Aromatase S
Ubiquitary occurrence: Flavonoids.
Polyphenols
• Flavonols (kaempferol, rutin, myricetin,
quercetin, spirenoside, galangin,
rhamnetin)
• Flavonones (hesperitin, naringin,
naringenin, hesperidin)
• Flavones (apigenin, flavone, luteolin,
chrysin, diosmetin, diosmin)
• Flavonolols (silibinin, silymarin, taxifolin)
• Flavan-3-ols (catechin)
• Isoflavones (genistein)
Aromatase
COX-2
Anti-oxidation
–
Vitamins A, C, E, and provitamins, e.g.,
lycopene (= 9,9-carotene), beta-carotene,
xanthophylls, tomatine, solanin
• Tomato (Solanum lycopersicum)
• Watermelon
• Cantaloupe
• Pink grapefruit
• Papaya
• Apricot
• Carrots
• Banana
Aromatase
COX-2
Cell signaling
–
Wholegrain, containing fiber, polyphenols,
fatty, and amino acids
• Buckwheat
• Millet
• Rye bread
• Brown rice
• Purple rice
Aromatase
Nuclear receptor
VEGF receptor
COX-2
–
For references see text.
• Buckwheat, millet, or brown and purple rice
• Cabbage, broccoli, cauliflower, kale, and bock choy
• Garlic and tomatoes as a result of indole-3 carbinol and
carotinoid (lycopin) content
• Mangosteen, grapefruits, and other citrus fruits as a result of
monoterpenes content
• Grapeseed due to procyanidin B dimer and resveratrol
• Pomegranates due to ellagitannins (the most potent being
urolithin B)
• And mushrooms (white button, baby button, shiitake,
portobello, and crimini) due to conjugated linoleic acid.
Induction of aromatase and thus increase of breast cancer risk
can be associated with ethanol. Liquorice (glycyrrhizin from
Frontiers in Nutrition | www.frontiersin.org 13 April 2020 | Volume 7 | Article 37
Jenzer and Sadeghi-Reeves Nutrigenomics Impacts on Aromatase Function
glycyrrhiza glabra) reduces serum testosterone and induces
ovulation by induction of aromatase (85–90).
Various flavonoids have been tested and the effect been
quantified on cell lines only, but not in vivo (e.g., H295R
adrenocortical carcinoma cells). Chalcones and flavanones
such as naringenin and hesperetin, flavones such as rotenone
or luteolin, catechins such as theaflavin or stilbenoids such
as resveratrol are stronger than other flavonoid derivatives
(81, 91–94). Prophylaxis of breast cancer by flavonoid
intake depends on the amounts consumed. Also, a protein-
rich diet including 300 g soy protein corresponds to more
than 100 g isoflavones per day is having an effect in breast
cancer prevention. Although the potency of isoflavones
is a mere permille of physiological 17β-estradiol, it may
significantly modulate estradiol effects at the estradiol
receptors due to its high affinity for the α-receptor subtype,
inducing a competitive inhibition in this way. The relative
concentrations of estradiol and of isoflavones competing
for the receptor will determine the long-term prophylactic
success (95).
Some authors describe more precisely the presumed
mechanism of action of active ingredients. Purple rice extract
inhibit VEGF (vascular endothelial growth factor)-induced
angiogenesis at the cell surface receptor (96). Organosulfur
compounds from garlic and other allium species are able
to suppress cancer cell proliferation by inhibiting the cell
division cycle of phosphatases rather than aromatase (97). 36
ß-caryophyllene oxide’s target is the cell signaling cascade. Cell
growth is inhibited and apoptosis induced by the suppression
of PI3K (phosphatidylinositol 3 kinase) pathways and ROS
(reactive oxygen species)-mediated MAPKs (mitogen-activated
protein kinases) activation (98).
A further explanation for the inhibiting effect of flavonoids
on aromatase is the inhibition of activity and expression of
histone deacetylation. As acetylated histones widen DNA and
therefore favor transcription, this mechanism corresponds
to a procedure of switching genes on. Acetylation opens
chromatin and enables transcription. Therefore, inhibition of
acetylation might limit DNA replication in tumor tissues, an
important regulation of repressing cancer genes. Switching
off genes would be accomplished by silent (condensed)
chromatin, enhanced by methylation of cytosines and
deacetylation of histones. These switching genes on/switching
genes off mechanisms are highly important for epigenetic
labeling and adaption to changing environmental conditions
(99–101).
Epigenetics also seem to play an important role in these
interindividual differences. A study with 300’000 recruits from
the Dutch army showed that famine has a statistically significant
influence and that a fetal memory exists. Malnutrition during
the first trimester of pregnancy experienced by the mothers of
these recruits in 1944-45 (“hunger winter”) led to an elevated
rate of obesity of their sons by the age of 19. The cause was a
modification of methylation on the IGF2 gene which promotes
growth during pregnancy (102–104).
Traditional antioxidation diet is one of the most approved
explanation of inhibition of aromatase by phytonutrients
of flavonoid derivatives. However, this means as well that
flavonoids compete for the oxygen in the course of enzymatic
oxidoreduction, and therefore of aromatase-catalyzed conversion
of steroid precursors to estrogens.
Resveratrol
From resveratrol the two enantiomeres trans-(E)-resveratrol
and cis-(Z)-resveratrol exist. Due to the (E)-enantiomere’s
stilbenoid structure resembling to a partial structure of α,β-
unsaturated ketone of the steroid’s ring A, aromatase is inhibited
competitively by resveratrol (Figure 6). The trans-isomer is
more stable. Trans to cis somerization is facilitated by UV
light of 200–400 nm and high pH. Cis to trans conversion is
facilitated by visible light of 400–800 nm, high temperature,
and low pH. Roasting has a diminishing effect on polyphenolic
composition and antioxidant activity. Sources of resveratrol
comprise (105–113):
• Fresh grape skin: 50–100 µg/g
• Red wine: (98–1,803µg/g cis-resveratrol, 0.5–26µg/g trans-
resveratrol)
• Peanuts skin: 0.02–1.79 µg/g
• Strawberry: 0.83 µg/g
• Hop: 0.23–2.28 µg/g
• Common buckwheat: 0.98–1.68 µg/g
• Tartary buckwheat: 3.43–3.5 µg/g.
Nutrigenomics and Further OMICS Technologies
The human body encodes approximately 50 members of nuclear
hormone receptors on the DNA, consisting of DNA-binding and
ligand binding domains. A number of cysteine residues binds
zinc ions to stabilize the structure of these zinc-finger domains of
steroid receptors. The impact of mutations on the genetic coding,
currently known as single nucleotide polymorphisms (SNPs),
is a key issue to prevent mistranscription and mistranslation
(e.g., “the sun is now red” 6= “the sun is not red”). Genomics,
transcriptomics, proteomics, metabolomics, and other omics
technologies have been identified as key technologies to find
answers to unresolved questions such as to why individuals
respond differently to equal bioactives1. During aromatase and
SERM treatment, “either de novo or acquired resistance is seen
with many patients. With de novo resistance, due to reduced
influence of estrogen receptors (ER) activity in these types of
tumors, there is no response to a drug upon initial treatment.
Furthermore, some patients acquire resistance after initially
responding to a drug treatment while still maintaining ER
expression. This strongly suggests that ER may still play an
important role after acquiring resistance to anti-hormonal drugs
has developed.” Reasons for resistance comprise (77):
• Mutations and/or variants of estrogen receptors and
of aromatase
• Modifications of the apoprotein of aromatase in its post-
transcriptional or post-translational biosynthesis
• SNPs of enzymes involved in aromatase’s prosthetic group
biosynthesis, i.e., heme biosynthesis
• Modifications in the cell-signaling pathways triggered by
docking substrates at the estrogen receptor.
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Endocrine resistance is not yet fully understood. More research
is needed in order to develop target specific drugs not affected
by endocrine resistance. Apart from inborn errors in direct
biosynthesis pathways, the all enzymes involved in the underlying
biosynthesis pathways (up to multiple levels upstream) such
as the porphyrin biosynthesis are important elements of an
overall functioning metabolism. The ALA-synthetase catalyzed
formation of δ-aminolevulinic acid, starting from succinate and
glycine, is the first and rate-limiting step of heme biosynthesis.
There is a particular role of the vitamin b12—tetrahydrofolate—
methionine/homocysteine system as carriers of methyl bricks.
The need of these carriers for heme biosynthesis explains why
not every anemia is an iron anemia and therefore cannot
be treated by iron supplementation. It may be diagnosed
as pernicious anemia due to a vitamin b12 deficiency. Iron
is only the last piece introduced as central atom and co-
factor to the heme moiety (114). The same as for porphyrin
biosynthesis is applicable for steroid biosynthesis via cholesterol.
This biochemical pathway starts from various sources such
as glycolysis or beta-oxidation bringing up AcCoA bricks.
Assembling these C2 units up to cholesterol is rate-limited by the
HMG-CoA-reductase step. Even the arborization to the sexual
steroids starting from cholesterol and progesterone involves
more than 30 enzymes in the biosynthesis of 17β-estradiol. The
whole system is highly regulated and equilibrated (115). A single
inborn error in a relevant biosynthetic step may dramatically
change this equilibrium. To diagnose an inborn error in the
steroid metabolism would need first the identification of genes
associated with the disease, commonly assumed by consortia
research. The whole genomes of participants with a disease
and healthy people need to be sequenced and plotted in a
Manhattan plot depicting the abundancy of SNPs (y-axis) against
all chromosomes (x-axis). The most abundant SNPs are likely to
include the genes responsible for a disease.
Omics technologies include genomics, transcriptomics,
proteomics, metabolomics, and many more. Neglecting genes
and their impact on phenotypes bears a high risk for biases
or confounding for study outcomes. Genetic heterogeneity
must therefore be included in clinical trials to omit type II
errors arising from unequal randomization to study groups.
For example, a new drug presumed to be more potent than a
Gold Standard cannot be recognized in a clinical trial in case the
treatment group counts more fast metabolizers compared to the
control group (Figure 7).
Most of the genomic DNA sequence differences between
any two people are common single nucleotide polymorphisms
(SNPs) with a minor allele frequency of more than 5% as
related to the wild type. The common disease—common variant
hypothesis expresses the fact of genetic risk as being due to
common SNPs (116). Very rare allele frequency may have a
high effect size. They cause Mendeleian diseases of high interest
for prenatal medical genetic screening, e.g., phenylketonuria,
cystic fibrosis. The penetration of this disease is complete. A
mutated gene causes the disease. On the other hand, common
allele frequencies with high effects on common diseases are rare.
Their penetration is only partial, i.e., an allele is not necessarily
determining a disease. Such polymorphisms are neutral or
only mildly harmful with respect to survival of a person or
of a species as long as alternative metabolic pathways permit
bypassing rate-limiting and committed enzymatic reactions. In
the band between evolutionary pressure and statistical power are
included high effect sizes for rare diseases, low-frequency variants
with intermediate effects, and common variants implicated in
common diseases. There are many non-communicable diseases
in oncology (with some 114 predisposing genes known),
psychiatry, obesity, or type 2 diabetes mellitus which can be
associated with lifestyle. Rare variants of small effects are difficult
to be identified by genetic means, and only rare examples
are known for high-effect common variants causing common
diseases (117).
Whereas, genome-wide associations can detect reliably genes
of Mendeleian inherited disease, it is more complex for
syndromes with a polygenic risk. Many of the associated genes
with such diseases such as obesity are not causal but only
tagging a causal marker. After many generations, tags disappear,
the disease-causing alleles persist, a phenomenon known as
linkage disequilibrium. Consortia activities contribute most to
the increasing knowledge about these diseases. Results cannot
simply be transferred to all populations because European
ancestry is overrepresented as compared to the global population
(118). Another shortcoming of GWAS studies is their statistical
character. The higher a sample size, the more significant hits will
result. First attempts efforts to associate genes with psychiatric
diseases were not successful. In 2009, with 2,601 cases with no
hits were detected whereas with 36,000 cases in 2014, 108 hits
resulted (119).
As far as ethnicity, the Indian subcontinent shows high
incidence cardio-vascular diseases causing four times higher risks
of heart attack before the age of 50 and high death rates in 1 of
3 persons fading away before the age of 65. In this population
group, high gestational diabetes and metabolic syndrome rates
are encountered more often than in any other ethnicity. These
diseases are obviously caused by a set of many single nucleotide
polymorphisms (SNPs) and thus bear a polygenetic risk
arising among others from genes coding for interleukin-6 (IL-
6), methylenetetrahydrofolate reductase (MTHFR), intercellular
adhesionmolecule (ICAM-1), a membrane protein stimulated by
retinoic acid (STRA6), or retinol binding protein 4 (RBP4) (120).
DISCUSSION
The Relevance of Nutrigenomics and
Further OMICS Technologies
As depicted repeatedly above, nutrigenomics becomes relevant
for the interpretation of antitumoral effects and further
interactions of foodstuff with genes, for potential errors
encountered in clinical studies without genomic testings
performed on the study population, or in public health as related
to non-communicable diseases. Genes code both for metabolism-
relevant enzymes and for receptors or targets of medicines
and nutrients.
Looking at a person’s family roots, it is of interest for
both the individual and researcher to know the risks for
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FIGURE 7 | The importance of considering genetic heterogeneity and individual requirements in research and therapy. (A) A group of study participants with equally
frequent fast and normal metabolizers. (B) Small study groups might suffer from unequally distributed fast and normal metabolizers. A presumably more potent new
drug could not be recognized in this case. This leads to bias and confounding due to negligence of genetic profiling. Example: the ratio in the treatment group is 3
normal and 7 fast metabolizers. The better effect of the new drug is not recognized. The hypothesis that the new drug is more potent would be rejected. This is a type
II error.
developing obesity in later life. Obesity is an epidemy worldwide
and associated with many health problems, amongst others
diabetes, cardiovascular diseases, and cancer. There is a clear
(epi)genetic component to a predisposition to obesity. In the last
decade, genome-wide studies analyzed hundreds of thousands
of SNPs (single nucleotide polymorphisms) and led to a better
understanding of the genetic causes of obesity. By 2012, 40 locis
were described and associated with obesity and BMI (body mass
index). So, slim father and obesemother, or the other way around,
whose alleles are found in the siblings? Among at least 65 relevant
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enzyme’s determining energy metabolism, which ones are coding
for deficiencies leading to inborn errors associated with obesity
albeit in the carbohydrate (glycolysis) or in the lipid metabolism
(beta-oxidation) or in in the energy production (citric acid
cycle, respiratory chain). The impact of nutrigenomics might
be a suitable motivation for nutrition researchers to override
some decades of very modest concrete results output and
recognize precise relationships between nutritional behavior and
disease. Patients suffering worldwide from obesity are waiting for
explanations regarding why they are concerned by this disease.
Public health and one-fits-all approaches in nutrition do
not satisfy requirements of therapeutic precision in times of
personalized nutrition. Physiological and biochemical processes
in vivo are the result of an individual metabolism which is
expressed as encoded by its genes. The individualized capacity
of metabolism is affecting qualitative and quantitative uptake
of nutrients and xenobiotics in the pharmaco- and nutrient-
kinetics steps even before a substrate has found its target.
It is continued when the substrate is binding to the fitting
physiological receptor. Due to the genetic code this one can
be configured qualitatively and quantitatively in a different way
than in another person. Nutrigenomics is therefore an emerging
research topic to support medical genetics and modern cell
and gene therapy of diseases such as spinal atrophy, sickle-cell
anemia, many inherited oncological diseases. Whereas, testing a
SNP is easy and routine meanwhile, coping with polygenic risks
will remain a challenge for the next decades.
What has been widely practiced in pharmacotherapy is
urgently needed to be applied in nutritional sciences. Traditional
nutrition research did not succeed to put out breakthroughs in
the past decades. Epidemiological and qualitative questionnaires-
dominated methodologies suffered from serious biases and
confounding. Generalizations to whole populations were made
although results were just applicable for a defined study
population and regional behaviors.
Summary of Main Findings
Public health dominated research is more and more competed
by personalized research approaches. Themystery of biochemical
pathways applies commonalities as long as the mechanisms and
principles of anabolism and catabolism are in the focus. On a
quantitative level however, a person’s metabolic capacity depends
on his or her individual genetic pattern.
Absorption of nutrients and xenobiotics is mainly an
individualized procedure depending on a human being’s
metabolic capacity. This in turn varies with age, gender, ethnicity,
and inherited metabolic performance. It is gender-, age-, and
ethnic-dependent whether an individuum can be attributed to
a certain group of metabolizers. Depending on the age and
gender, the ratios of body compartments vary and therefore
the distribution according to the hydrophilic—lipophilic profile
of a substrate. Metabolism is discussed mainly in terms of the
hepatic part due to its predominance, although it happens also
in extra hepatic hormone-dependent tissues. The role of CYP450
isoenzymes is a central and determining one as it does not
only act as monooxygenase to detoxify but also to biosynthesize
from metabolites further hormonal active substances such as
estrogens. The mechanisms of action and the catalytic cycles
themselves depend on further enzymes, which are themselves
highly regulated. Excretion is often discussed as an isolated
procedure. However, the Bateman function describing the course
of plasma level is in fact the sum of absorption, distribution,
metabolism, and excretion.
On a pharmaco- and nutrient-dynamic level, aromatase as
central interest of this review and target of the precursors of
estrogens is also a main target of medicines used in breast
cancer treatment. Nutrients of the flavonoid group are partially
structurally similar to estradiol precursors testosterone and
androstendione. They have a relevant potential to prevent breast
cancer and to be used as adjuvants in pharmacotherapy.
Knowing biochemistry of pharmacokinetics (LADME) and
pharmacodynamics as well as biosynthesis of the main carriers
and enzymes of these procedures is not enough. As the metabolic
capacity of a person is depending on the genome and various
circumstances relevant for the expression of these genes, non-
communicable diseases cannot be prevented in the population
by treating specific pathways without considering genetics
and epigenetics.
Genetic regulation of metabolism is a complex procedure
affecting multiple pathways. All ATP-dependent metabolic
steps need an effective glycolysis (for pyruvate and acetyl-
CoA production), citric acid cycle (for electron harvesting),
and respiratory chain/oxidative phosphorylation (for ATP
replenishment). Fine-tuning this kind of energy production
depends therefore on co-enzymes (B-vitamins) and co-factors
(mainly iron, copper). Energy production in combination to
gene regulation by “anti-oxidant” nutrients are key elements for
cancer prevention and add-on therapies parallel to conventional
cytotoxic protocols.
In most of the cases, to obtain an entirely well-resolved picture
of a pathogenic situation, there is a need to know underlying
biochemical pathways. Therefore, an inborn error of metabolism
ending up in manifest breast tumor needs to be assessed within
the affected tissue, the involved physiological substrates and
metabolites, the capacity of enzymes involved in these steps,
the capacity of underlying biochemical pathways, and finally
the genotype and phenotype of the patient. It may even be
wise to evaluate environmental circumstances, epigenetics, and
immunological enhancers or inhibitors.
With the infinite number of recombination of the genes,
each person is unique, and all diagnosis must consider the
genetic patterns with numbers of SNPs leading to differences in
liberation, absorption, distribution, metabolism, and excretion of
nutrients from a food matrix. A variable uptake of bioactives is
the first quantitative difference in nutritional therapy. Receptors
of any two persons may differ in their number and in
their structure. These differences potentiate the quantitative
differences of a response to nutrients intake.
Limitations
Although scientific publications have been carefully selected, not
all are arising from evidence-based findings of clinical trials.
Some interpretations and statements are based on biochemically
and pharmaceutically accepted theories and state of the art.
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Commonalities and principles have been proved over centuries.
Evidence can only be generated if methodologies are convincing.
However, many publications are limited to regional or ethnical
frames and cannot be transferred to other ethnicities. And
many studies are erroneous, because genetic profiling has
been neglected. It is preferable to interpret and reevaluate
carefully some findings from early publications as soon as new
knowledge is emerging on a novel research field. Often, early
findings remain standards although new insight hints at pitfalls
in methodologies.
The statements made in this article might be countered in later
research activities.
CONCLUSION
Nutrition science needs to consider the genome of an individual
to truly find answers to nutrition-derived non-communicable
diseases. All steps from intake to effect are genetically encoded.
Genetic tests to detect risks for pathologies and determine
optimal individual diets should be considered in nutrition
research and practices. With current GWAS approaches,
inherited errors of metabolism are identified and ideally treated
effectively as long as the one variant—one disease hypothesis
is applicable. It is much more difficult to get a precise genetic
profile for multifactorially caused non-communicable diseases.
Polygenic risks are feasible but diagnostic tools are not yet
available in a desired extent. As to whether explanations beyond
pure chemical mechanisms of action are described in the
literature, the answer is that neither authors, nor providers of
genetic testing kits are going into the details needed for a truly
personalized nutritional medicine. The next step with sequencing
the whole exome is on the threshold of becoming routine
diagnosis. The further step of sequencing the entire genome will
bring the desired details such as regulation option by intron-
coded miRNA and further nucleic acid or protein fragments. On
this way, actual genetic testing is only an intermediate sojourn on
the way to whole genome sequencing.
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